6 Red Days In A Row: Beam Therapeutics Stock Is Down 19%
A biotech name is on a multi-day slide, and the numbers show a sharp contrast between its growth and its profitability.
Beam Therapeutics (BEAM) Inc. develops precision genetic medicines for patients suffering from serious diseases, and the market has just pushed its stock lower for 6 consecutive trading days. The cumulative loss over this streak is 18.7%, a move that has erased about $731 million from the company’s market value, which now stands at about $3.2 billion.
The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia, and also develops therapies for other liver, muscle, and central nervous system disorders.
BEAM Versus The S&P 500, Streak And Beyond
- Why Is NVDA Stock The Discount Option Among Its Peers?
- The Real Engine Driving Netflix Stock Is Its Earnings Power
- Tesla Stock’s Future Comes With A Hefty Price Tag
- The Premium On Airbnb Keeps Growing. So Does The Case For Booking
- Why Abbott Stock Is Reimagining Its Future
- What’s Happening With GE Stock?
Here is how BEAM stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | BEAM | S&P 500 |
|---|---|---|
| 1D | -0.2% | 0.4% |
| 6D (Current Streak) | -18.7% | 0.9% |
| 1M (21D) | 6.2% | 1.9% |
| 3M (63D) | 1.8% | 8.7% |
| YTD 2026 | 11.3% | 10.6% |
| 2025 | 11.8% | 16.4% |
| 2024 | -8.9% | 23.3% |
| 2023 | -30.4% | 24.2% |
The market is weighing deep losses against high growth.
The numbers suggest the selling may have fundamental reasons. Beam’s operating margin over the last twelve months is -226.6%, and it trades at a price-to-earnings multiple of -49.0. These figures stand against S&P 500 medians of 18.4% and 24.2, respectively. While the company’s revenue grew 158.0% over the last twelve months, far outpacing the S&P median of 7.5%, its profitability metrics show significant strain.
This pressure is specific to the stock. Over the same 6 trading days, the S&P 500 returned +0.9%. And while streaks draw attention, they are not uncommon; currently, 29 S&P 500 stocks are on winning streaks of three days or more, while 34 are on losing streaks.
A streak is a signal to re-evaluate, not a command to act.
A persistent move in one direction is information. It tells you where market momentum and investor attention are focused, but it is not an instruction. The disciplined response is to check the business realities against the new price. The data here allows for that first step, framing a company with considerable revenue growth but also considerable operating losses.
A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
Those watching the group rather than this one name have another route: a biotech ETF like XBI owns the whole group. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
Weakness In One Name Should Be Noise, Not News
For a diversified holder, a streak like this is a data point. For a concentrated one, it is a hole in the plan. The difference is never the stock; it is the portfolio built around it.
Building that portfolio is what the Trefis High Quality (HQ) Portfolio does: roughly 30 businesses with the cash generation and balance-sheet strength to absorb a bad month, selected and rebalanced by rules. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Make the next streak, in either direction, someone else’s drama.